CAJ | 학술논문

目的：观察恩替卡韦（ETV）治疗慢性乙型肝炎的临床疗效。方法36例慢性乙型肝炎患者包括初治治疗组（20例）和阿德福韦酯（ADV）耐药组（16例），两组患者分别给予ETV 0.5 mg口服，1次/d，治疗96周。结果 ETV初治组和ADV耐药组患者治疗96周后，ALT复常率分别为100%和93.75%，差异无统计学意义（χ2=4.553，P＞0.05）；HBV DNA低于检测下限的比率均为100%；HBeAg阴转率分别为42.8%和40.0%，差异无统计学意义（χ2=0.422，P ＞0.05）；HBeAg血清学转换率分别为21.4%和20.0%，差异无统计学意义（χ2=0.059，P＞0.05）。两组患者耐受性均良好，无明显不良反应。结论 ETV治疗慢性乙型肝炎，对初治及阿德福韦耐药患者均能有效地控制病毒复制，改善肝功能，促使HBeAg血清学转换，长期服药安全性好。
목적：관찰은체잡위（ETV）치료만성을형간염적림상료효。방법36례만성을형간염환자포괄초치치료조（20례）화아덕복위지（ADV）내약조（16례），량조환자분별급여ETV 0.5 mg구복，1차/d，치료96주。결과 ETV초치조화ADV내약조환자치료96주후，ALT복상솔분별위100%화93.75%，차이무통계학의의（χ2=4.553，P＞0.05）；HBV DNA저우검측하한적비솔균위100%；HBeAg음전솔분별위42.8%화40.0%，차이무통계학의의（χ2=0.422，P ＞0.05）；HBeAg혈청학전환솔분별위21.4%화20.0%，차이무통계학의의（χ2=0.059，P＞0.05）。량조환자내수성균량호，무명현불량반응。결론 ETV치료만성을형간염，대초치급아덕복위내약환자균능유효지공제병독복제，개선간공능，촉사HBeAg혈청학전환，장기복약안전성호。
Objective To analyze the antiviral effects of enticavir in patients with hepatitis B. Methods Total of 36 patients with chronic hepatitis B including 20 na?ve patients and 16 patients with adefovir dipivoxil (ADV)-resistant, were treated with enticavir 0.5 mg daily. The efficacy was evaluated at 4th , 12th, 24th, 48th and 96th month, respectively. Results At 96th month after treatment, the rates of ALT becoming normal were 100%and 93.75%in na?ve and in ADV-resistant patients, respectively, with no signiifcant difference (χ2=4.553, P>0.05). The negative rats of HBV DNA of the two groups were all 100%. Negative rates of HBeAg of the two groups were 42.8%and 40.0%, with no signiifcant difference (χ2=0.422, P>0.05). The HBeAg seroconversion rate of the two groups were 21.4%and 20.0%, respectively, with no significant difference (χ2= 0.059,P > 0.05). The two groups were all well tolerated and had no obvious adverse reactions. Conclusions Entecavir could effectively inhibit the replication of HBV, normalize of ALT and enhance conversion from anti-HBe to HBeAg for cases with na?ve patients and patients with ADV-resistant. It is safey for long-term medication.